Listed drugmakers see marketing expenses fall in H1

Published: 2013-09-03 07:00:00

Updated: 2013-09-03 07:00:00

Korean drug manufacturers saw a contraction in their marketing outlays in the first half on a year-on-year basis, apparently hit by weaker bottom line due to the government-mandated cuts in drug prices last year.

According to a report released by Yakup.com, a pharmaceutical information portal,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK